theNNT.com recently published a review of the evidence behind statins for people with low cardiovascular risk:
“The USPSTF review found no increase in the risk of new-onset diabetes associated with statin therapy for primary prevention. However, the best predictor of developing statin-induced diabetes is diabetes risk, not cardiovascular risk. Therefore, analyzing exclusively primary prevention data may have underpowered the analysis. A 2010 meta-analysis of 13 trials with more than 90,000 patients, which is broadly cited as the most complete assessment of statin-induced diabetes, shows a 9% relative increase (not far from the USPSTF’s result of 5%) in diabetes risk. The absolute increase was 0.098% per year of statin exposure. This becomes 0.49% at five years, although the number will vary with diabetes risk, just as statin benefits vary with cardiovascular risk.”
Read the full review for the full summary as well as caveats.